Pulmonary delivery of anti‐inflammatory siRNA holds great potential in mitigating the
cytokine storm during severe pneumonia. However, commonly utilized polycationic siRNA …

Pulmonary delivery of anti-inflammatory siRNA presents a promising approach for localized
therapy of acute lung injury (ALI), while polycationic vectors can be easily trapped by the …

The mucus layer and cell membrane are two major barriers against pulmonary siRNA
delivery. Commonly used polycationic gene vectors can hardly penetrate the mucus layer …

The use of small interfering RNAs (siRNAs) has been under investigation for the treatment of
several unmet medical needs, including acute lung injury/acute respiratory distress …

Clinical application of siRNA-based therapeutics outside of the liver has been hindered by
the inefficient delivery of siRNA effector molecules into extra-hepatic organs and cells of …

Uncontrolled inflammation is responsible for acute and chronic diseases in the lung.
Regulating expression of pro-inflammatory genes in pulmonary tissue using small interfering …

Asthma is a worldwide health problem. Activated T cells (ATCs) in the lung, particularly T
helper 2 cells (Th 2), are strongly associated with inducing airway inflammatory responses …

Interleukin-11 (IL-11) is a profibrotic cytokine essential for the differentiation of fibroblasts
into collagen-secreting, actin alpha 2, smooth muscle–positive (ACTA2+) myofibroblasts …

Lung diseases are the leading cause of mortality worldwide. The currently available
therapies are not sufficient, leading to the urgent need for new therapies with sustained anti …

The local delivery of small interfering RNA (siRNA) to the lungs may provide a therapeutic
solution to a range of pulmonary disorders. Resident alveolar macrophages (rAM) in the …